Literature DB >> 21442686

Pharmacy student driven detection of adverse drug reactions in the community pharmacy setting.

Søren Troels Christensen1, Birthe Søndergaard, Per Hartvig Honoré, Ole Jannik Bjerrum.   

Abstract

PURPOSE: Post-marketing safety studies of adverse drug reactions (ADRs) form an important part of pharmacovigilance. Countries having a formal pharmacovigilance system to a large extent rely on voluntary ADR reporting from health professionals through spontaneous report systems. The contribution of pharmacists in ADR reporting, although varies significantly among countries. Pharmacists in community pharmacies are in a unique position for detection of experienced ADRs by the drug users. The study reports from a study on community pharmacy internship students' proactive role in ADR detection through direct encountering and questioning with drug users.
METHOD: Pharmacy students undertaking internship in a community pharmacy were approached. Thirteen students from nine community pharmacies participated in the project as data collectors. Prior to the study students attended an educational seminar focusing on ADR detection and reporting in general. Ibuprofen was chosen as the drug of study. Pharmacy students approached recurrent drug users purchasing the drug. Participating users were asked about experienced ADRs linked to ibuprofen use. Reported ADRs were collected and analysed.
RESULTS: Hundred and twenty eight ibuprofen users participated in the study out of who thirty three reported forty five ADRs possibly linked to ibuprofen use. The reported ADRs followed earlier reported patterns of distribution with gastric pain showing up as the most commonly reported symptom followed by heartburn, nausea, diarrhoea and constipation.
CONCLUSIONS: Through adequate training community pharmacy internship students get competencies and are capable of detecting and reporting ADRs through direct questions to drug users.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21442686     DOI: 10.1002/pds.2069

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  6 in total

1.  Community pharmacists' knowledge, behaviors and experiences about adverse drug reaction reporting in Saudi Arabia.

Authors:  Mansour Adam Mahmoud; Yazed Alsowaida; Thamir Alshammari; Tahir Mehmood Khan; Alian Alrasheedy; Mohamad Azmi Hassali; Hisham Aljadhey
Journal:  Saudi Pharm J       Date:  2013-08-21       Impact factor: 4.330

2.  Teaching Pharmacovigilance to Undergraduate Students: Our Experience in Poor-Resource Setting.

Authors:  Mohammed Alshakka; Wafa Badullah; Abdullah Al-Dhuraibi; Sara Alshagga; Mohamed Izham Mohamed Ibrahim
Journal:  J Pharm Bioallied Sci       Date:  2022-05-19

3.  Barriers to reporting of adverse drugs reactions: a cross sectional study among community pharmacists in United Kingdom.

Authors:  Ejaz Cheema; Abdul Haseeb; Tahir M Khan; Paul Sutcliffe; Donald R Singer
Journal:  Pharm Pract (Granada)       Date:  2017-08-08

4.  Effect of an educational intervention on knowledge and attitude regarding pharmacovigilance and consumer pharmacovigilance among community pharmacists in Lalitpur district, Nepal.

Authors:  Nisha Jha; Devendra Singh Rathore; Pathiyil Ravi Shankar; Shital Bhandary; Rabi Bushan Pandit; Sudesh Gyawali; Mohamed Alshakka
Journal:  BMC Res Notes       Date:  2017-01-03

5.  What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects.

Authors:  Rike van Eekeren; Leàn Rolfes; Andries S Koster; Lara Magro; Gurumurthy Parthasarathi; Hussain Al Ramimmy; Tim Schutte; Daisuke Tanaka; Eugène van Puijenbroek; Linda Härmark
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

Review 6.  Urgent need to modernize pharmacovigilance education in healthcare curricula: review of the literature.

Authors:  Michael Reumerman; J Tichelaar; B Piersma; M C Richir; M A van Agtmael
Journal:  Eur J Clin Pharmacol       Date:  2018-06-20       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.